QS200

QS200 is an investigational **injectable stem cell synthetic hydrogel product candidate** being developed by Qrons for traumatic brain injury, particularly diffuse axonal injury and concussion. Public company materials describe it as an **MSC synthetic hydrogel** platform and external pipeline sources classify it as a **cell replacement** therapy in preclinical development for brain injuries. Qrons has also disclosed patent activity around **therapeutic polypseudorotaxane hydrogels** intended for central nervous system pathologies, suggesting QS200 is a regenerative neurorepair product that combines modified mesenchymal stem cells with a synthetic hydrogel scaffold to support neuronal repair and tissue regeneration after injury. The precise molecular mechanism, manufacturing composition, and administration details have not been fully disclosed in the accessible public sources.